A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two parts: PF-07799544 as a single agent (Phase 1a) and PF-07799544 in combination with another study medicine called PF-07799933 (Phase 1b). Phase 1a is no longer open for enrollment. In Phase1b (noted as "this study"), we are seeking participants who have: * a solid tumor which is metastatic or recurrent (excluding colorectal cancer) * tumor with the mutation (a

Trial Details

NCT ID
NCT05538130
Phase
PHASE1
Sponsor
Pfizer
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • PF-07799544
  • PF-07799933
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Fayetteville, Arkansas, United States|36.06258,-94.15743
  • Los Angeles, California, United States|34.05223,-118.24368
  • Pasadena, California, United States|34.14778,-118.14452
  • Tampa, Florida, United States|27.94752,-82.45843

Key Eligibility Criteria

  • Diagnosis of advanced/metastatic solid tumor (excluding colorectal cancer)
  • Measurable disease by RECIST version 1.1
  • Evidence of a BRAF V600 mutation
  • Prior therapy per tumor cohort

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →